Conquering Diseases

Study Of An Investigational Drugs Containing Monoclonal Antibodies For Mild To Moderate Covid-19 (Blaze 4)

Description

Seeking men and women with mild to moderate COVID-19 for a study of an investigational drug that contains monoclonal antibodies.

Overview

We are studying whether an investigational drug containing one or more monoclonal antibodies is more effective than treatment with a placebo (looks like the investigational drug but contains no medicine) for mild to moderate COVID-19. Participants have a one in five chance of receiving the placebo or a single investigational drug. The rest will receive a combination of investigational drugs. All participants will also receive the standard treatment for COVID-19.

What we're hoping for

We hope to evaluate whether the investigational drug containing monoclonal antibodies is safe and effective in treating mild to moderate COVID-19 illness.

Additional Information

ClinicalTrials.gov Identifier: NCT04634409

 Principal Investigator

Robert  Finberg, MD

University of Massachusetts Medical School

 Study Contact

Shestruma  Parajuli

shestruma.parajuli@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989